Osteoporosis in older persons: current pharmacotherapy and future directions

Abstract

Introduction: Osteopororic fractures are highly prevalent in older persons having catastrophic consequences in their quality of life and increasing disability and mortality in this population. The mechanisms of osteoporosis in older persons are unique in terms of cellular changes and response to osteoporosis treatment. Therefore, specifically targeted treatments are required in this particular population.

Areas covered: This paper provides an overview on the particular mechanisms of osteoporosis in older persons and the current and future therapeutic strategies to improve bone mass and prevent fractures in this population.

Expert opinion: Osteoporosis in older persons (especially in the old–old) has a unique pathophysiology that predisposes them to fractures thus having catastrophic consequences. Identification of patients at risk followed by therapies targeted to their cellular changes is pivotal to close the care gap observed in osteoporosis, predominantly in the older population. The treatment of osteoporosis has evolved from daily to yearly dosing thus facilitating compliance and effectiveness. It is expected that future biologically targeted treatments will have a similar separate dosing regime with better anti-fracture efficacy and lower incidence of side effects.

Keywords::

• alendronate
• anabolics
• anti-resorptives
• bisphosphonates
• bone biomarkers
• bone mineral density
• Cathepsin K
• denosumab
• elderly
• fractures
• older persons
• osteoblast
• osteoclast
• osteoporosis
• risedronate
• sclerostin
• teriparatide

Notes

This box summarizes key points contained in the article.